PubMed Health. A service of the National Library of Medicine, National Institutes of Health.

Monroe AK, Gudzune KA, Sharma R, et al. Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2014 Feb. (Comparative Effectiveness Reviews, No. 132.)

Appendix DList of Excluded Articles

No Original Data

  1. Roth EM, Rosenson RS, Jones PH, Davidson MH, Kelly MT, Setze CM, Lele A, Thakker K. Attainment of goal/desirable lipid levels in patients with mixed dyslipidemia after 12 weeks of treatment with fenofibric acid and rosuvastatin combination therapy: A pooled analysis of controlled studies. J Clin Lipidol. 2012:534–44. [PubMed: 23312049]
  2. Ma L, Ballantyne CM, Belmont JW, Keinan A, Brautbar A. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. J Lipid Res. 2012:2425–8. [PMC free article: PMC3466010] [PubMed: 22896670]
  3. Hingorani AD, Sofat R, Morris RW, Whincup P, Lowe GD, Mindell J, Sattar N, Casas JP, Shah T. Is it important to measure or reduce C-reactive protein in people at risk of cardiovascular disease? Eur Heart J. 2012:2258–64. [PubMed: 22766581]
  4. Elmallah W, Krasuski RA. Therapy and clinical trials. Curr Opin Lipidol. 2011:512–3. [PubMed: 22101564]
  5. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (>/= 2 mg/L) J Clin Lipidol. 2011:401–7. cmb@bcm.tmc.edu. [PubMed: 21981842]
  6. Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Taggart W, Brudi P. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res. 2011:262–70. [PubMed: 21859750]
  7. Takagi H, Matsui M, Umemoto T. High-density lipoprotein-dependent effects of statins on the risk of coronary heart disease deaths and events. Int J Cardiol. 2011:377–9. [PubMed: 21851993]
  8. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012:486–94. [PMC free article: PMC3279312] [PubMed: 21798891]
  9. Idris I, Tate H, Ahmad A, McCormack T. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study. J Clin Lipidol. 2011:316–23. [PubMed: 21784378]
  10. Farnier M, Taggart W, Dong Q, Lin J, Shah A, Brudi P. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. J Clin Lipidol. 2011:179–87. [PubMed: 21600523]
  11. Spertus J. Clinical trial subgroups: challenges and opportunities in describing the benefits of therapy. Circ Cardiovasc Qual Outcomes. 2011:266–7. [PubMed: 21586724]
  12. Mohiuddin SM, Thakker KM, Setze CM, Kelly MT. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. Curr Med Res Opin. 2011:1067–78. [PubMed: 21438793]
  13. ASCOT analysis with atorvastatin shows limits of CRP as indicator of cardiovascular risk. Cardiovasc J Afr. 2011:51. [PubMed: 21298210]
  14. Yip A, Hegele RA. Lipid modification in the elderly using the combination of a statin and a cholesterol absorption inhibitor. Expert Opin Pharmacother. 2011:675–8. [PubMed: 21294698]
  15. Goldberg AC, Bittner V, Pepine CJ, Kelly MT, Thakker K, Setze CM, Lele A, Sleep DJ. Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia. Am J Cardiol. 2011:898–905. [PubMed: 21247520]
  16. Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2011:47–57. [PMC free article: PMC3070080] [PubMed: 21174145]
  17. Breimer LH, Mikhailidis DP. Trials by independent expert bodies. Arch Intern Med. 2010:2042. author reply 2043-4. [PubMed: 21149770]
  18. Bays H, Conard S, Leiter LA, Bird S, Jensen E, Hanson ME, Shah A, Tershakovec AM. Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading? Lipids Health Dis. 2010:136. [PMC free article: PMC3012666] [PubMed: 21118495]
  19. Vega de Ceniga M. Comments regarding ‘A randomised placebo-controlled double-blind trial to evaluate lipid-lowering pharmacotherapy on proteolysis and inflammation in abdominal aortic aneurysms’ Eur J Vasc Endovasc Surg. 2011:36–7. [PubMed: 20961777]
  20. Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol. 2010:609–19. [PubMed: 20960535]
  21. Leiter LA, Bays H, Conard S, Lin J, Hanson ME, Shah A, Tershakovec AM. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. Int J Clin Pract. 2010:1765–72. [PubMed: 20946261]
  22. Bays HE, Conard SE, Leiter LA, Bird SR, Lowe RS, Tershakovec AM. Influence of age, gender, and race on the efficacy of adding ezetimibe to atorvastatin vs. atorvastatin up-titration in patients at moderately high or high risk for coronary heart disease. Int J Cardiol. 2011:141–7. [PubMed: 20837371]
  23. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation. 2010:850–2. [PubMed: 20733114]
  24. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010:331–88. [PubMed: 20664824]
  25. Rotella CM, Zaninelli A, Le Grazie C, Hanson ME, Gensini GF. Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes. Lipids Health Dis. 2010:80. [PMC free article: PMC2918617] [PubMed: 20663203]
  26. Bays HE, Roth EM, McKenney JM, Kelly MT, Thakker KM, Setze CM, Obermeyer K, Sleep DJ. The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia. Diabetes Care. 2010:2113–6. [PMC free article: PMC2928374] [PubMed: 20573750]
  27. Reckless J, Davies G, Tunceli K, Hu XH, Brudi P. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health. 2010:726–34. [PubMed: 20561328]
  28. Bader T. The myth of statin-induced hepatotoxicity. Am J Gastroenterol. 2010:978–80. [PubMed: 20445507]
  29. Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010:133–47. [PubMed: 20401351]
  30. Ferrario CM. ARBITER 6-HALTS. Does it have the power to settle all matters? Ther Adv Cardiovasc Dis. 2010:77–81. [PubMed: 20360390]
  31. Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010:210–8. [PubMed: 20151997]
  32. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, Tomassini JE, Tershakovec AM. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes Care. 2010:1021–4. [PMC free article: PMC2858166] [PubMed: 20150290]
  33. Jones PH, Cusi K, Davidson MH, Kelly MT, Setze CM, Thakker K, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. Am J Cardiovasc Drugs. 2010:73–84. [PubMed: 20136164]
  34. Zhao XQ, Krasuski RA, Baer J, Whitney EJ, Neradilek B, Chait A, Marcovina S, Albers JJ, Brown BG. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS) Am J Cardiol. 2009:1457–64. [PMC free article: PMC2829987] [PubMed: 19932775]
  35. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009:601–10. [PubMed: 19929597]
  36. Kastelein JJ, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. N Engl J Med. 2009:2180–3. [PubMed: 19915218]
  37. Farmer J. The Vytorin on Carotid-Media Thickness and Overall Arterial Rigidity (VYCTOR) study. Expert Rev Cardiovasc Ther. 2009:1057–60. [PubMed: 19764858]
  38. Steiner G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. Cardiovasc Drugs Ther. 2009:403–8. [PubMed: 19757004]
  39. Miller D. Fear of statins? CMAJ. 2009:399. [PMC free article: PMC2742130] [PubMed: 19752144]
  40. Califf RM, Harrington RA, Blazing MA. Premature release of data from clinical trials of ezetimibe. N Engl J Med. 2009:712–7. [PubMed: 19675335]
  41. Statins reduce stroke risk by one-fifth. Cardiovasc J Afr. 2009:208–9. [PubMed: 19575094]
  42. Goumas GS. LDL-Cholesterol is the King. Angiology. 2009:387–8. [PubMed: 19497926]
  43. Jones PH, Davidson MH, Goldberg AC, Pepine CJ, Kelly MT, Buttler SM, Setze CM, Lele A, Sleep DJ, Stolzenbach JC. Efficacy and safety of fenofibric acid in combination with a statin in patients with mixed dyslipidemia: Pooled analysis of three phase 3, 12-week randomized, controlled studies. J Clin Lipidol. 2009:125–37. [PubMed: 21291802]
  44. Farmer JA. Simvastatin with or without ezetimibe in familial hypercholesterolemia (the ENHANCE trial) Curr Atheroscler Rep. 2009:81–2. [PubMed: 19228478]
  45. Bays HE, Jones PH, Mohiuddin SM, Kelly MT, Sun H, Setze CM, Buttler SM, Sleep DJ, Stolzenbach JC. Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia. J Clin Lipidol. 2008:426–35. [PubMed: 21291776]
  46. Vo AN, Kashyap ML. Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders. Expert Rev Cardiovasc Ther. 2008:1303–10. [PubMed: 19018682]
  47. Donner-Banzhoff N, Sonnichsen A. Statins and primary prevention of cardiovascular events. BMJ. 2008:a2576. [PubMed: 19010973]
  48. Dobson R. Trial stopped early after rosuvastatin found to cut the risk of heart attack and stroke by 44% in healthy people. BMJ. 2008:a2523. [PubMed: 19004893]
  49. Wilensky RL. Vulnerable plaque: scope of the problem. J Interv Cardiol. 2008:443–51. [PubMed: 18973505]
  50. Ginsberg HN, Ramakrishnan R. Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. Arterioscler Thromb Vasc Biol. 2008:1685–6. [PMC free article: PMC3275632] [PubMed: 18799794]
  51. Fleming TR. Identifying and addressing safety signals in clinical trials. N Engl J Med. 2008:1400–2. [PMC free article: PMC2703718] [PubMed: 18768938]
  52. Peto R, Emberson J, Landray M, Baigent C, Collins R, Clare R, Califf R. Analyses of cancer data from three ezetimibe trials. N Engl J Med. 2008:1357–66. [PubMed: 18765432]
  53. O'Keefe JH, Bybee KA, Lavie CJ. Intensive lipid intervention in the post-ENHANCE era. Mayo Clin Proc. 2008:867–9. [PubMed: 18674470]
  54. Toutouzas P, Richter D. Carotid intima-media thickness (cIMT): a useful clinic tool or research luxury? Another view of the ENHANCE trial. Angiology. 2008:77S–9S. [PubMed: 18628278]
  55. ENHANCE results: a surrogate trial that impacts beyond size and scope. Cardiovasc J Afr. 2008:166–8. [PubMed: 18568183]
  56. Serebruany VL. Controlled Rosuvastatin Multinational Trial In Heart Failure (the positive negative trial) Am J Cardiol. 2008:1808–9. [PubMed: 18549865]
  57. Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, Tershakovec AM. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J Clin Lipidol. 2008:91–105. [PubMed: 21291725]
  58. Karam JG, Loney-Hutchinson L, McFarlane SI. High-dose atorvastatin after stroke or transient ischemic attack: The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. J Cardiometab Syndr. 2008:68–9. [PubMed: 18326981]
  59. Extended ASCOT - lipid lowering (ASCOT-LLA) study shows positive results of atorvastatin. Cardiovasc J Afr. 2008:49–51. [PubMed: 18320090]
  60. Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Lin J, Shah A, Tershakovec AM. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008:25–35. [PubMed: 21291712]
  61. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008:249–59. [PubMed: 18053317]
  62. Tomillero A, Moral MA. Summary. Methods Find. Exp. Clin. Pharmacol. 2010:331–388. [PubMed: 20664824]
  63. Davidson MH. Should niacin be the preferred drug to add to a statin? Curr. Cardiol. Rep. 2010:447–449. [PubMed: 20820952]
  64. Reiner Z. Combination therapy with prescription omega-3-acid ethyl esters and statin improves non-HDL-C more effectively than statin alone. Clinical Lipidology. 2010:325–328.
  65. Kastelein JJP, Bots ML. Statin therapy with ezetimibe or niacin in high-risk patients. New Engl. J. Med. 2009:2180–2183. [PubMed: 19915218]
  66. Yasu T. JELIS study. Jpn. J. Clin. Pharmacol. Ther. 2008:167–168.
  67. Wiklund O, Bondjers G, Wright I, Camejo G. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Atherosclerosis. 96:57–67. [PubMed: 8929256]
  68. Pearson T, Ballantyne C, Sisk C, Shah A, Veltri E, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am J Cardiol. 2007:1706–1713. [PubMed: 17560879]
  69. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008:2052–8. [PubMed: 18451347]
  70. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag. 2007:159–64. [PMC free article: PMC1994036] [PubMed: 17583186]
  71. Abate N, Catapano AL, Ballantyne CM, Davidson MH, Polis A, Smugar SS, Tershakovec AM. Effect of ezetimibe/simvastatin versus atorvastatin or rosuvastatin on modifying lipid profiles in patients with diabetes, metabolic syndrome, or neither: Results of two subgroup analyses. J Clin Lipidol. 2008:91–105. [PubMed: 21291725]

Not Full Report

  1. Farmer J. The Vytorin on Carotid-Media Thickness and Overall Arterial Rigidity (VYCTOR) study. Expert Rev Cardiovasc Ther. 2009:1057–60. [PubMed: 19764858]
  2. Toyama K, Sasaki O, Nishioka T, Ito H. Beneficial effect of eicosapentaenoic acid on endothelial function in old myocardial infarction patients under adequate statin therapy. J. Am. Coll. Cardiol. 2012:E1773.
  3. Dobs, et al. [Randomised double-blind dosetitration (to target low-density lipoprotein cholesterol) Phase 3 evaluation … provisional acceptance]. J Am Coll Cardiol. 2003:227A. [abstract]

Not in English

  1. Namal E, Sener N, Ulas T, Akcali Z, Oztekin E, Borlu F. [Effects of different statins, ezetimibe/simvastatin combination on hsCRP levels in unstable angina pectoris and non-ST elevation myocardial infarction patients: a randomized trial]. Anadolu Kardiyol Derg. 2011:703–10. [PubMed: 22088858]
  2. Karbasi-Afshar R, Shahmari A, Shafighi N, Saburi A. Effects of simvastatin with or without fenofibrate on echocardiographic findings of patients with coronary artery disease and dyslipidemia: A brief report. Tehran Uni. Med. J. 2012:378–382.
  3. Safarova M, Trukhacheva E, Ezhov M, Afanasieva O, Tripoten M, Pokrovsky S. Pleiotropic effects of niacin therapy in addition to atorvastatin in coronary heart disease patients with elevated lipoprotein(A) levels. Atheroscler. Suppl. 2011:69.
  4. Yasu T. JELIS study. Jpn. J. Clin. Pharmacol. Ther. 2008:167–168.
  5. Yamagishi T. [Efficacy and safety of ezetimibe added on to rosuvastatin (2.5 mg) compared with uptitration of rosuvastatin (5 mg) in hyperlipidemic patients]. LA: Jpn. Japanese Pharmacology and Therapeutics. 2010:305–11.
  6. Dobs, et al. [Randomised double-blind dosetitration (to target low-density lipoprotein cholesterol) Phase 3 evaluation … provisional acceptance]. J Am Coll Cardiol. 2003:227A. [abstract]

Children Study

  1. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagne C, Shi G, Veltri E, Avis HJ, Kastelein JJ. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008:1421–9. [PubMed: 18940534]

Healthy Subjects

  1. Zinellu A, Sotgia S, Loriga G, Deiana L, Satta AE, Carru C. Oxidative stress improvement is associated with increased levels of taurine in CKD patients undergoing lipid-lowering therapy. Amino Acids. 2012:1499–507. [PubMed: 22278741]
  2. Robinson JG, Ballantyne CM, Hsueh W, Rosen J, Lin J, Shah A, Lowe RS, Hanson ME, Tershakovec AM. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study) J Clin Lipidol. 2011:474–82. [PubMed: 22108151]
  3. Liu PY, Liu YW, Lin LJ, Chen JH, Liao JK. Evidence for statin pleiotropy in humans: differential effects of statins and ezetimibe on rho-associated coiled-coil containing protein kinase activity, endothelial function, and inflammation. Circulation. 2009:131–8. [PMC free article: PMC2745913] [PubMed: 19075102]
  4. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra VK, Affrime MB. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002:309–19. [PMC free article: PMC1874429] [PubMed: 12236852]

Not RCT or Extension

  1. Reyes-Soffer G, Ngai CI, Lovato L, Karmally W, Ramakrishnan R, Holleran S, Ginsberg HN. Effect of Combination Therapy With Fenofibrate and Simvastatin on Postprandial Lipemia in the ACCORD Lipid Trial. Diabetes Care. 2013:422–8. [PMC free article: PMC3554305] [PubMed: 23033246]
  2. Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One. 2012:e35298. [PMC free article: PMC3327654] [PubMed: 22523582]
  3. Sawayama Y, Maeda S, Ohnishi H, Hayashi S, Hayashi J. Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. Clin Drug Investig. 2010:157–66. [PubMed: 20155988]
  4. Abel T, Feher J, Dinya E, Eldin MG, Kovacs A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009:MS6–11. [PubMed: 19946244]
  5. Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther. 2009:267–76. [PubMed: 19650249]
  6. Poldermans D, Dunkelgrun M, Schouten O, Hostalek U. Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands. Eur Surg Res. 2008:313–8. [PubMed: 18799884]
  7. Liska B, Khattab AA, Herrmann L, Abdel-Wahab M, Westphal R, Tolg R, Geist V, Richardt G. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets. Herz. 2008:362–7. [PubMed: 18773156]
  8. Mayne J, Dewpura T, Raymond A, Cousins M, Chaplin A, Lahey KA, Lahaye SA, Mbikay M, Ooi TC, Chretien M. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans. Lipids Health Dis. 2008:22. [PMC free article: PMC2432057] [PubMed: 18547436]

Drug Is Not Approved

  1. Ballantyne C, Gleim G, Liu N, Sisk CM, Johnson-Levonas AO, Mitchel Y. Effects of coadministered extended-release niacin/laropiprant and simvastatin on lipoprotein subclasses in patients with dyslipidemia. J Clin Lipidol. 2012:235–43. [PubMed: 22658147]

Not Relevant to Key Question

  1. Bahlmann E, Gerdts E, Cramariuc D, Gohlke-Baerwolf C, Nienaber CA, Wachtell K, Seifert R, Chambers JB, Kuck KH, Ray S. Prognostic Value of Energy Loss Index in Asymptomatic Aortic Stenosis. Circulation. 2013 [PubMed: 23357717]
  2. Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Diabetes Obes Metab. 2012 [PubMed: 23279632]
  3. Kinouchi K, Ichihara A, Bokuda K, Morimoto S, Itoh H. Effects of Adding Ezetimibe to Fluvastatin on Kidney Function in Patients with Hypercholesterolemia: a Randomized Control Trial. J Atheroscler Thromb. 2012 [PubMed: 23197250]
  4. Philpott AC, Hubacek J, Sun YC, Hillard D, Anderson TJ. Niacin improves lipid profile but not endothelial function in patients with coronary artery disease on high dose statin therapy. Atherosclerosis. 2013:453–8. [PubMed: 23174368]
  5. Berthold HK, Berneis K, Mantzoros CS, Krone W, Gouni-Berthold I. Effects of simvastatin and ezetimibe on interleukin-6 and high-sensitivity C-reactive protein. Scand Cardiovasc J. 2013:20–7. [PubMed: 23013513]
  6. Buldak L, Dulawa-Buldak A, Labuzek K, Okopien B. Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose. Int J Clin Pharmacol Ther. 2012:805–13. [PubMed: 22943927]
  7. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study) Am J Cardiol. 2012:984–92. [PubMed: 22819432]
  8. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, Milionis HJ. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013:5–12. [PubMed: 22573476]
  9. Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Saku K. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol. 2012:111–8. [PubMed: 22542530]
  10. Guyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care. 2012:857–60. [PMC free article: PMC3308290] [PubMed: 22338103]
  11. Toth PP, Thakker KM, Jiang P, Padley RJ. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag. 2012:39–44. [PMC free article: PMC3273410] [PubMed: 22323895]
  12. Sasaki J, Miwa T, Odawara M. Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr J. 2012:297–304. [PubMed: 22293584]
  13. Hing Ling PK, Civeira F, Dan AG, Hanson ME, Massaad R, De Tilleghem Cle B, Milardo C, Triscari J. Ezetimibe/simvastatin 10/40 mg versus atorvastatin 40 mg in high cardiovascular risk patients with primary hypercholesterolemia: a randomized, double-blind, active-controlled, multicenter study. Lipids Health Dis. 2012:18. [PMC free article: PMC3306831] [PubMed: 22293030]
  14. Sasaki J, Yokoyama M, Matsuzaki M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Itakura H, Hishida H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y. Relationship between coronary artery disease and non-HDL-C, and effect of highly purified EPA on the risk of coronary artery disease in hypercholesterolemic patients treated with statins: sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) J Atheroscler Thromb. 2012:194–204. [PubMed: 22186099]
  15. Elmallah W, Krasuski RA. Therapy and clinical trials. Curr Opin Lipidol. 2011:512–3. [PubMed: 22101564]
  16. Farnier M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin. Lipids Health Dis. 2011:212. [PMC free article: PMC3250955] [PubMed: 22087637]
  17. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011:2255–67. [PubMed: 22085343]
  18. Ballantyne CM, Davidson MH, Setze CM, Kelly MT. Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (>/= 2 mg/L) J Clin Lipidol. 2011:401–7. cmb@bcm.tmc.edu. [PubMed: 21981842]
  19. Brautbar A, Covarrubias D, Belmont J, Lara-Garduno F, Virani SS, Jones PH, Leal SM, Ballantyne CM. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia. Atherosclerosis. 2011:737–42. [PubMed: 21889769]
  20. Tsunoda R, Sakamoto T, Kojima S, Ogata Y, Kitagwa A, Ogawa H. Recurrence of angina pectoris after percutaneous coronary intervention is reduced by statins in Japanese patients. J Cardiol. 2011:208–15. [PubMed: 21872439]
  21. Schuchardt JP, Neubronner J, Kressel G, Merkel M, von Schacky C, Hahn A. Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: Results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids. 2011:381–6. [PubMed: 21862301]
  22. Takagi H, Matsui M, Umemoto T. High-density lipoprotein-dependent effects of statins on the risk of coronary heart disease deaths and events. Int J Cardiol. 2011:377–9. [PubMed: 21851993]
  23. Ramos SC, Fonseca FA, Kasmas SH, Moreira FT, Helfenstein T, Borges NC, Moreno RA, Rezende VM, Silva FC, Izar MC. The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr J. 2011:80. [PMC free article: PMC3159132] [PubMed: 21810257]
  24. Sever PS, Poulter NR, Chang CL, Hingorani A, Thom SA, Hughes AD, Welsh P, Sattar N. Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J. 2012:486–94. [PMC free article: PMC3279312] [PubMed: 21798891]
  25. Idris I, Tate H, Ahmad A, McCormack T. Concordance between plasma apolipoprotein B levels and cholesterol indices among patients receiving statins and nonstatin treatment: Post-hoc analyses from the U.K. InPractice study. J Clin Lipidol. 2011:316–23. [PubMed: 21784378]
  26. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial) Am J Cardiol. 2011:682–90. [PubMed: 21683321]
  27. Krysiak R, Zmuda W, Okopien B. The effect of ezetimibe, administered alone or in combination with simvastatin, on lymphocyte cytokine release in patients with elevated cholesterol levels. J Intern Med. 2012:32–42. [PubMed: 21623963]
  28. Farnier M, Taggart W, Dong Q, Lin J, Shah A, Brudi P. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients. J Clin Lipidol. 2011:179–87. [PubMed: 21600523]
  29. West AM, Anderson JD, Meyer CH, Epstein FH, Wang H, Hagspiel KD, Berr SS, Harthun NL, DiMaria JM, Hunter JR, Christopher JM, Chew JD, Winberry GB, Kramer CM. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis. 2011:156–62. [PMC free article: PMC3157540] [PubMed: 21570685]
  30. Dong L, Kerwin WS, Chen H, Chu B, Underhill HR, Neradilek MB, Hatsukami TS, Yuan C, Zhao XQ. Carotid artery atherosclerosis: effect of intensive lipid therapy on the vasa vasorum--evaluation by using dynamic contrast-enhanced MR imaging. Radiology. 2011:224–31. [PMC free article: PMC3121009] [PubMed: 21493792]
  31. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol: baseline characteristics of study participants. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: impact on Global Health outcomes (AIM-HIGH) trial. Am Heart J. 2011:538–43. [PMC free article: PMC3120223] [PubMed: 21392609]
  32. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am Heart J. 2011:471–477 e2. [PMC free article: PMC3120226] [PubMed: 21392600]
  33. Krysiak R, Okopien B. The effect of ezetimibe and simvastatin on monocyte cytokine release in patients with isolated hypercholesterolemia. J Cardiovasc Pharmacol. 2011:505–12. [PubMed: 21297492]
  34. Dobiasova M, Frohlich J, Sedova M, Cheung MC, Brown BG. Cholesterol esterification and atherogenic index of plasma correlate with lipoprotein size and findings on coronary angiography. J Lipid Res. 2011:566–71. [PMC free article: PMC3035693] [PubMed: 21224290]
  35. Rosenson RS, Carlson DM, Kelly MT, Setze CM, Hirshberg B, Stolzenbach JC, Williams LA. Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus. Cardiovasc Drugs Ther. 2011:47–57. [PMC free article: PMC3070080] [PubMed: 21174145]
  36. Kim SH, Park K, Hong SJ, Cho YS, Sung JD, Moon GW, Yoon MH, Lee MY, Hyon MS, Kim DW, Kim HS. Efficacy and tolerability of a generic and a branded formulation of atorvastatin 20 mg/d in hypercholesterolemic Korean adults at high risk for cardiovascular disease: a multicenter, prospective, randomized, double-blind, double-dummy clinical trial. Clin Ther. 2010:1896–905. [PubMed: 21095484]
  37. Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, Dong Q, Shah A, Brudi P. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis. 2010:127. [PMC free article: PMC2992529] [PubMed: 21050476]
  38. Pepine CJ, Jacobson TA, Carlson DM, Kelly MT, Setze CM, Gold A, Stolzenbach JC, Williams LA. Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies. Clin Cardiol. 2010:609–19. [PubMed: 20960535]
  39. Leiter LA, Bays H, Conard S, Lin J, Hanson ME, Shah A, Tershakovec AM. Attainment of Canadian and European guidelines' lipid targets with atorvastatin plus ezetimibe vs. doubling the dose of atorvastatin. Int J Clin Pract. 2010:1765–72. [PubMed: 20946261]
  40. Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012:61–74. [PubMed: 20626402]
  41. Reckless J, Davies G, Tunceli K, Hu XH, Brudi P. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study. Value Health. 2010:726–34. [PubMed: 20561328]
  42. McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. Int J Clin Pract. 2010:1052–61. [PubMed: 20487050]
  43. Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy. Am J Cardiol. 2010:1409–12. [PubMed: 20451686]
  44. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, Weissman NJ, Griffen L, Taylor AJ. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol. 2010:2721–6. [PubMed: 20399059]
  45. Ferrario CM. ARBITER 6-HALTS. Does it have the power to settle all matters? Ther Adv Cardiovasc Dis. 2010:77–81. [PubMed: 20360390]
  46. Kater AL, Batista MC, Ferreira SR. Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe. Metabolism. 2010:921–6. [PubMed: 20199786]
  47. Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010:907–15. [PubMed: 20156032]
  48. Sawayama Y, Maeda S, Ohnishi H, Hayashi S, Hayashi J. Efficacy and safety of ezetimibe for Japanese patients with dyslipidaemia: The ESSENTIAL Study. Clin Drug Investig. 2010:157–66. [PubMed: 20155988]
  49. Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol. 2010:487–94. [PubMed: 20152243]
  50. Origasa H, Yokoyama M, Matsuzaki M, Saito Y, Matsuzawa Y. Clinical importance of adherence to treatment with eicosapentaenoic acid by patients with hypercholesterolemia. Circ J. 2010:510–7. [PubMed: 20145342]
  51. Bays HE, McKenney J, Maki KC, Doyle RT, Carter RN, Stein E. Effects of prescription omega-3-acid ethyl esters on non--high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin. Mayo Clin Proc. 2010:122–8. [PMC free article: PMC2813819] [PubMed: 20118387]
  52. Davidson MH, Rooney MW, Drucker J, Eugene Griffin H, Oosman S, Beckert M. Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study. Clin Ther. 2009:2824–38. [PubMed: 20110022]
  53. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009:56. [PMC free article: PMC2803170] [PubMed: 20017910]
  54. Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC. Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study. Clin Drug Investig. 2010:51–61. [PubMed: 19995098]
  55. Lakoski SG, Xu F, Vega GL, Grundy SM, Chandalia M, Lam C, Lowe RS, Stepanavage ME, Musliner TA, Cohen JC, Hobbs HH. Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. J Clin Endocrinol Metab. 2010:800–9. [PMC free article: PMC3079219] [PubMed: 19965915]
  56. Zhao XQ, Krasuski RA, Baer J, Whitney EJ, Neradilek B, Chait A, Marcovina S, Albers JJ, Brown BG. Effects of combination lipid therapy on coronary stenosis progression and clinical cardiovascular events in coronary disease patients with metabolic syndrome: a combined analysis of the Familial Atherosclerosis Treatment Study (FATS), the HDL-Atherosclerosis Treatment Study (HATS), and the Armed Forces Regression Study (AFREGS) Am J Cardiol. 2009:1457–64. [PMC free article: PMC2829987] [PubMed: 19932775]
  57. Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Metab Syndr Relat Disord. 2009:601–10. [PubMed: 19929597]
  58. Jakulj L, Vissers MN, Groen AK, Hutten BA, Lutjohann D, Veltri EP, Kastelein JJ. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res. 2010:755–62. [PMC free article: PMC2842149] [PubMed: 19828909]
  59. Florentin M, Kostapanos MS, Nakou ES, Elisaf M, Liberopoulos EN. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia. J Cardiovasc Pharmacol Ther. 2009:274–82. [PubMed: 19724023]
  60. Sang ZC, Wang F, Zhou Q, Li YH, Li YG, Wang HP, Chen SY. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chin Med J (Engl) 2009:1615–20. [PubMed: 19719960]
  61. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Fukami K, Okuda S, Yamagishi S. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010:58–61. [PubMed: 19666118]
  62. Derosa G, D'Angelo A, Franzetti IG, Ragonesi PD, Gadaleta G, Scalise F, Ciccarelli L, Piccinni MN, Cicero AF. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. J Clin Pharm Ther. 2009:267–76. [PubMed: 19650249]
  63. Settergren M, Bohm F, Ryden L, Pernow J, Kalani M. Lipid lowering versus pleiotropic effects of statins on skin microvascular function in patients with dysglycaemia and coronary artery disease. J Intern Med. 2009:492–8. [PubMed: 19563393]
  64. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009:1973–83. [PubMed: 19555253]
  65. Oikawa S, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis. 2009:535–9. [PubMed: 19447387]
  66. Matsuzaki M, Yokoyama M, Saito Y, Origasa H, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Matsuzawa Y. Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ J. 2009:1283–90. [PubMed: 19423946]
  67. Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, Geisen U, Abletshauser C, Hoffmann MM. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009:463–70. [PubMed: 19397693]
  68. Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lutjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res. 2009:2117–23. [PMC free article: PMC2739752] [PubMed: 19380898]
  69. Zema MJ. Add-on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statin-treated patients. J Clin Lipidol. 2009:119–24. [PubMed: 21291801]
  70. Tremblay AJ, Lamarche B, Hogue JC, Couture P. Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia. J Lipid Res. 2009:1463–71. [PMC free article: PMC2694344] [PubMed: 19305020]
  71. Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol. 2009:33–8. [PubMed: 21291786]
  72. Nomura S, Inami N, Shouzu A, Omoto S, Kimura Y, Takahashi N, Tanaka A, Urase F, Maeda Y, Ohtani H, Iwasaka T. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009:16–22. [PubMed: 19172517]
  73. Strony J, Hoffman R, Hanson M, Veltri E. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients. Clin Ther. 2008:2280–97. [PubMed: 19167588]
  74. Fleg JL, Mete M, Howard BV, Umans JG, Roman MJ, Ratner RE, Silverman A, Galloway JM, Henderson JA, Weir MR, Wilson C, Stylianou M, Howard WJ. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol. 2008:2198–205. [PMC free article: PMC2854549] [PubMed: 19095139]
  75. Davidson MH, Abate N, Ballantyne CM, Catapano AL, Xu X, Lin J, Rosenberg E, Tershakovec AM. Ezetimibe/simvastatin compared with atorvastatin or rosuvastatin in lowering to specified levels both LDL-C and each of five other emerging risk factors for coronary heart disease: Non-HDL-cholesterol, TC/HDL-C, apolipoprotein B, apo-B/apo-A-I, or C-reactive protein. J Clin Lipidol. 2008:436–46. [PubMed: 21291777]
  76. Strony J, Yang B, Hanson ME, Veltri EP. Long-term safety and tolerability of ezetimibe coadministered with simvastatin in hypercholesterolemic patients: a randomized, 12-month double-blind extension study. Curr Med Res Opin. 2008:3149–57. [PubMed: 18842166]
  77. Westerweel PE, Visseren FL, Hajer GR, Olijhoek JK, Hoefer IE, de Bree P, Rafii S, Doevendans PA, Verhaar MC. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. Eur Heart J. 2008:2808–17. [PubMed: 18824462]
  78. Hamilton-Craig IR. After ENHANCE: the cholesterol hypothesis is alive and well. Med J Aust. 2008:303–4. [PubMed: 18803531]
  79. Ginsberg HN, Ramakrishnan R. Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results. Arterioscler Thromb Vasc Biol. 2008:1685–6. [PMC free article: PMC3275632] [PubMed: 18799794]
  80. Liska B, Khattab AA, Herrmann L, Abdel-Wahab M, Westphal R, Tolg R, Geist V, Richardt G. Simvastatin and ezetimibe in addition to nonpharmacological risk factor modification for achieving new low-density lipoprotein cholesterol targets. Herz. 2008:362–7. [PubMed: 18773156]
  81. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol. 2008:145–50. [PubMed: 18670365]
  82. Saito Y, Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS) Atherosclerosis. 2008:135–40. [PubMed: 18667204]
  83. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008:2052–8. [PubMed: 18451347]
  84. Settergren M, Bohm F, Ryden L, Pernow J. Cholesterol lowering is more important than pleiotropic effects of statins for endothelial function in patients with dysglycaemia and coronary artery disease. Eur Heart J. 2008:1753–60. [PubMed: 18441323]
  85. Avisar I, Brook JG, Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med. 2008:203–8. [PubMed: 18395165]
  86. Extended ASCOT - lipid lowering (ASCOT-LLA) study shows positive results of atorvastatin. Cardiovasc J Afr. 2008:49–51. [PubMed: 18320090]
  87. May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study) Am J Cardiol. 2008:486–9. [PubMed: 18312763]
  88. Bays HE, Braeckman RA, Ballantyne CM, Kastelein JJ, Otvos JD, Stirtan WG, Soni PN. Icosapent ethyl, a pure EPA omega-3 fatty acid: Effects on lipoprotein particle concentration and size in patients with very high triglyceride levels (the MARINE study) J. Clin. Lipidology. 2012:565–572. [PubMed: 23312052]
  89. McBride R. Adding niacin to simvastatin did not improve clinical outcomes in patients with CV disease and dyslipidemia. Ann. Intern. Med. 2012:JC4–8. [PubMed: 22508748]
  90. Karbasi-Afshar R, Shahmari A, Saburi A. Echocardiographic and exercise test findings in patients with dyslipidemia and coronary artery disease before and after treatment with Simvastatin with or without fenofibrate. Iran. Cardiovasc. Res. J. 2012:143–147.
  91. Toyama K, Sasaki O, Nishioka T, Ito H. Beneficial effect of eicosapentaenoic acid on endothelial function in old myocardial infarction patients under adequate statin therapy. J. Am. Coll. Cardiol. 2012:E1773.
  92. Wakita Y, Wakida Y, Itou T, Mizuno R. High purity eicosapentaenoic acid in addition to a strong statin makes regression of coronary plaque in patients with angina pectoris. Circulation. 2011
  93. Insull W Jr., Toth PP, Superko HR, Thakkar RB, Krause S, Jiang P, Parreno RA, Padley RJ. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc. Health Risk Manage. 2010:1065–1075. [PMC free article: PMC3004509] [PubMed: 21191426]
  94. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, Ward MJA, Gudmundsen O, Vige R, Payne SPK, Ye S, Shearman CP, Gallagher PJ, Grimble RF, Calder PC. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability. Atherosclerosis. 2010:252–259. [PubMed: 20542512]
  95. Insull W Jr., Basile JN, Vo AN, Jiang P, Thakkar R, Padley RJ. Efficacy and safety of combination therapy with niacin extended-release and simvastatin versus atorvastatin in patients with dyslipidemia: The SUPREME Study. J. Clin. Lipidology. 2009:109–118. [PubMed: 21291800]
  96. Taylor AJ, Stanek EJ. Flushing and the HDL-C response to extended-release niacin. J. Clin. Lipidology. 2008:285–288. [PubMed: 21291745]
  97. Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006:772–8. [PMC free article: PMC2569293] [PubMed: 16749654]
  98. Geiss HC, Otto C, Parhofer KG. Effect of ezetimibe on low-density lipoprotein subtype distribution: results of a placebo-controlled, double-blind trial in patients treated by regular low-density lipoprotein apheresis and statins. Metabolism. 2006:599–604. [PubMed: 16631435]
  99. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006:385–95. [PubMed: 16490616]
  100. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother. 2005:218–28. [PubMed: 16503317]
  101. Athyros VG, Mikhailidis DP, Papageorgiou AA, Didangelos TP, Peletidou A, Kleta D, Karagiannis A, Kakafika AI, Tziomalos K, Elisaf M. Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism. 2005:1065–74. [PubMed: 16092057]
  102. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin. 2005:571–8. [PubMed: 15899106]
  103. Geiss HC, Otto C, Hund-Wissner E, Parhofer KG. Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins. Atherosclerosis. 2005:107–12. [PubMed: 15823282]
  104. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol. 2005:462–8. [PubMed: 15695129]
  105. Ballantyne CM, Miller E, Chitra R. Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther. 2004:1855–64. [PubMed: 15639697]
  106. Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial. Clin Ther. 2004:1599–607. [PubMed: 15598476]
  107. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004:3512–7. [PubMed: 15537681]
  108. Simons L, Tonkon M, Masana L, Maccubbin D, Shah A, Lee M, Gumbiner B. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr Med Res Opin. 2004:1437–45. [PubMed: 15383192]
  109. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004:1185–95. [PubMed: 15324521]
  110. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004:653–8. [PubMed: 15311720]
  111. Hong H, Xu ZM, Pang BS, Cui L, Wei Y, Guo WJ, Mao YL, Yang XC. Effects of simvastain combined with omega-3 fatty acids on high sensitive C-reactive protein, lipidemia, and fibrinolysis in patients with mixed dyslipidemia. Chin Med Sci J. 2004:145–9. [PubMed: 15250255]
  112. Kosoglou T, Statkevich P, Meyer I, Cutler DL, Musiol B, Yang B, Zhu Y, Maxwell SE, Veltri EP. Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin. Curr Med Res Opin. 2004:955–65. [PubMed: 15200755]
  113. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004:1487–94. [PubMed: 15194018]
  114. Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. Am J Cardiol. 2003:667–72. [PubMed: 12633795]
  115. Sager PT, Melani L, Lipka L, Strony J, Yang B, Suresh R, Veltri E. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003:1414–8. [PubMed: 14675576]
  116. Nordoy A, Svensson B, Hansen JB. Atorvastatin and omega-3 fatty acids protect against activation of the coagulation system in patients with combined hyperlipemia. J Thromb Haemost. 2003:690–7. [PubMed: 12871402]
  117. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002:1084–91. [PubMed: 12423708]
  118. Kosoglou T, Meyer I, Veltri EP, Statkevich P, Yang B, Zhu Y, Mellars L, Maxwell SE, Patrick JE, Cutler DL, Batra VK, Affrime MB. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Br J Clin Pharmacol. 2002:309–19. [PMC free article: PMC1874429] [PubMed: 12236852]
  119. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002:2377–86. [PubMed: 12145148]
  120. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002:1198–202. [PubMed: 12087019]
  121. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002:429–36. [PubMed: 12059988]
  122. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002:877–83. [PubMed: 12029003]
  123. Hunninghake D, Insull W Jr, Toth P, Davidson D, Donovan JM, Burke SK. Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis. 2001:407–16. [PubMed: 11583720]
  124. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001:467–74. [PubMed: 11403509]
  125. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis. 2001:7–16. [PubMed: 11383326]
  126. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001:544–8. [PMC free article: PMC1729738] [PubMed: 11303007]
  127. Nordoy A, Bonaa KH, Sandset PM, Hansen JB, Nilsen H. Effect of omega-3 fatty acids and simvastatin on hemostatic risk factors and postprandial hyperlipemia in patients with combined hyperlipemia. Arterioscler Thromb Vasc Biol. 2000:259–65. [PubMed: 10634827]
  128. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis. 98:197–203. [PubMed: 9568752]
  129. Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 98:163–70. [PubMed: 9566646]
  130. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 97:797–8. [PubMed: 9315596]
  131. Wiklund O, Bondjers G, Wright I, Camejo G. Insoluble complex formation between LDL and arterial proteoglycans in relation to serum lipid levels and effects of lipid lowering drugs. Atherosclerosis. 96:57–67. [PubMed: 8929256]
  132. Vanhanen HT, Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 95:135–46. [PubMed: 7661873]
  133. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 95:480–4. [PubMed: 7653448]
  134. Vacek JL, Dittmeier G, Chiarelli T, White J, Bell HH. Comparison of lovastatin (20 mg) and nicotinic acid (1.2 g) with either drug alone for type II hyperlipoproteinemia. Am J Cardiol. 95:182–4. [PubMed: 7611158]
  135. Smit JW, Jansen GH, de Bruin TW, Erkelens DW. Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. Am J Cardiol. 95:126A–128A. [PubMed: 7604787]
  136. Wiklund O, Angelin B, Bergman M, Berglund L, Bondjers G, Carlsson A, Linden T, Miettinen T, Odman B, Olofsson SO, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med. 93:13–20. [PubMed: 8420296]
  137. O'Brien RC, Simons LA, Clifton P, Cooper ME, Jennings GL, Jerums G, Nestel PJ, Sullivan D. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust. 90:480–3. [PubMed: 2199801]
  138. Liu M, Wallmon A, Wallin R, et al. Effects of stable fish oil and simvastatin on plasma lipoproteins in patients with hyperlipidemia. Nutr Res. 2003:1027–34.
  139. van Dam M, Kastelein J. Efficacy and tolerability of fluvastatin in a titration dosage regimen in hyperlipidaemic patients: Results of a multicentre phase IV study. Clin Drug Investig. 2001:477–84.
  140. Ojala JP, Helve E, Karjalainen K, Tarkkanen A, Tikkanen MJ. Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Atherosclerosis. 90:85–95. [PubMed: 2360923]
  141. Mol MJ, Stuyt PM, Demacker PN, Stalenhoef AF. The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia. Neth J Med. 90:182–90. [PubMed: 2355995]
  142. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007:767–75. [PubMed: 17407633]
  143. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007:1090–8. [PubMed: 17398308]
  144. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study) Am J Cardiol. 2007:673–80. [PubMed: 17317370]
  145. Patel JV, Hughes EA. Efficacy, safety and LDL-C goal attainment of ezetimibe 10 mg-simvastatin 20 mg vs. placebo-simvastatin 20 mg in UK-based adults with coronary heart disease and hypercholesterolaemia. Int J Clin Pract. 2006:914–21. [PubMed: 16893434]
  146. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006:703–12. [PubMed: 16872244]
  147. Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res. 2006:93–102. [PubMed: 17058629]
  148. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006:873–83. [PubMed: 16709309]
  149. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006:396–401. [PubMed: 16843192]
  150. Pearson TA, Denke MA, McBride PE, Battisti WP, Gazzara RA, Brady WE, Palmisano J. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc. 2006:1177–85. [PubMed: 16970214]
  151. Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007:1354–67. [PubMed: 17825687]
  152. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007:357–63. [PubMed: 17461981]
  153. Meyer BJ, Hammervold T, Rustan AC, Howe PR. Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects. Lipids. 2007:109–15. [PubMed: 17393216]
  154. Bays HE, McGovern ME. Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin. Prev Cardiol. 2005:226–33. [PubMed: 16230877]
  155. Shankar PK, Bhat R, Prabhu M, Reddy BP, Reddy MS, Reddy M. Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India. J Clin Lipidol. 2007:264–70. [PubMed: 21291690]
  156. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006:743–5. [PubMed: 16950175]
  157. Napoli C, Lepore S, Chiariello P, Condorelli M, Chiariello M. Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia. J Cardiovasc Pharmacol Ther. 97:17–26. [PubMed: 10684438]
  158. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008:1431–43. [PubMed: 18376000]
  159. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA. Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial. J Cardiovasc Pharmacol Ther. 96:107–116. [PubMed: 10684407]
  160. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008:490–6. [PubMed: 18312764]
  161. Heinonen TM, Schrott H, McKenney JM, Sniderman AD, Broyles FE, Zavoral JH, Kivel F, Black DM. Atorvastatin, a New HMG-CoA Reductase Inhibitor as Monotherapy and Combined With Colestipol. J Cardiovasc Pharmacol Ther. 96:117–122. [PubMed: 10684408]
  162. Tanaka K, Ishikawa Y, Yokoyama M, Origasa H, Matsuzaki M, Saito Y, Matsuzawa Y, Sasaki J, Oikawa S, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke. 2008:2052–8. [PubMed: 18451347]
  163. Ballantyne CM, Davidson MH, McKenney J, Keller LH, Bajorunas DR, Karas RH. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study) Am J Cardiol. 2008:1428–36. [PubMed: 18471454]
  164. Turk TR, Voropaeva E, Kohnle M, Nurnberger J, Philipp T, Kribben A, Heemann U, Witzke O. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008:369–73. [PubMed: 17956887]
  165. Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, Stier S, Ko Y, Patel D, Soutar AK, Seedorf U, Mantzoros CS, Plat J, Krone W. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008:198–207. [PubMed: 17980884]
  166. Ose L, Johnson-Levonas A, Reyes R, Lin J, Shah A, Tribble D, Musliner T. A multi-centre, randomised, double-blind 14-week extension study examining the long-term safety and efficacy profile of the ezetimibe/simvastatin combination tablet. Int J Clin Pract. 2007:1469–80. [PubMed: 17655686]
  167. Moore A, Phan BA, Challender C, Williamson J, Marcovina S, Zhao XQ. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol. 2007:620–5. [PubMed: 21291704]
  168. Taylor AJ, Zhu D, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. Vasc Health Risk Manag. 2007:159–64. [PMC free article: PMC1994036] [PubMed: 17583186]

Other

  1. Madan M, Vira T, Rampakakis E, Gupta A, Khithani A, Balleza L, Vaillancourt J, Boukas S, Sampalis J, de Carolis E. A Randomized Trial Assessing the Effectiveness of Ezetimibe in South Asian Canadians with Coronary Artery Disease or Diabetes: The INFINITY Study. Adv Prev Med. 2012. 103728. [PMC free article: PMC3529456] [PubMed: 23304534]
  2. Florentin M, Liberopoulos EN, Rizos CV, Kei AA, Liamis G, Kostapanos MS, Elisaf MS. Colesevelam Plus Rosuvastatin 5 mg/Day Versus Rosuvastatin 10 mg/Day Alone on Markers of Insulin Resistance in Patients with Hypercholesterolemia and Impaired Fasting Glucose. Metab Syndr Relat Disord. 2012 [PubMed: 23170931]
  3. Agouridis AP, Kostapanos MS, Tsimihodimos V, Kostara C, Mikhailidis DP, Bairaktari ET, Tselepis AD, Elisaf MS. Effect of rosuvastatin monotherapy or in combination with fenofibrate or omega-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome. Int J Clin Pract. 2012:843–53. [PubMed: 22897461]
  4. Ma L, Ballantyne CM, Belmont JW, Keinan A, Brautbar A. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia. J Lipid Res. 2012:2425–8. [PMC free article: PMC3466010] [PubMed: 22896670]
  5. Okada K, Iwahashi N, Endo T, Himeno H, Fukui K, Kobayashi S, Shimizu M, Iwasawa Y, Morita Y, Wada A, Shigemasa T, Mochida Y, Shimizu T, Sawada R, Uchino K, Umemura S, Kimura K. Long-term effects of ezetimibe-plus-statin therapy on low-density lipoprotein cholesterol levels as compared with double-dose statin therapy in patients with coronary artery disease. Atherosclerosis. 2012:454–6. [PubMed: 22892323]
  6. Sasaki J, Otonari T, Sawayama Y, Hata S, Oshima Y, Saikawa T, Biro S, Kono S. Double-dose pravastatin versus add-on ezetimibe with low-dose pravastatin - effects on LDL cholesterol, cholesterol absorption, and cholesterol synthesis in Japanese patients with hypercholesterolemia (PEAS study) J Atheroscler Thromb. 2012:485–93. [PubMed: 22659533]
  7. Zinellu A, Sotgia S, Pisanu E, Loriga G, Deiana L, Satta AE, Carru C. LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy. Eur J Pharm Sci. 2012:117–23. [PubMed: 22659373]
  8. Yu CC, Lai WT, Shih KC, Lin TH, Lu CH, Lai HJ, Hanson ME, Hwang JJ. Efficacy, safety and tolerability of ongoing statin plus ezetimibe versus doubling the ongoing statin dose in hypercholesterolemic Taiwanese patients: an open-label, randomized clinical trial. BMC Res Notes. 2012:251. [PMC free article: PMC3403927] [PubMed: 22621316]
  9. Semb AG, Kvien TK, DeMicco DA, Fayyad R, Wun CC, LaRosa JC, Betteridge J, Pedersen TR, Holme I. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum. 2012:2836–46. [PubMed: 22576673]
  10. Kouvelos GN, Arnaoutoglou EM, Matsagkas MI, Kostara C, Gartzonika C, Bairaktari ET, Milionis HJ. Effects of rosuvastatin with or without ezetimibe on clinical outcomes in patients undergoing elective vascular surgery: results of a pilot study. J Cardiovasc Pharmacol Ther. 2013:5–12. [PubMed: 22573476]
  11. Arimura T, Miura S, Ike A, Sugihara M, Iwata A, Nishikawa H, Kawamura A, Saku K. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol. 2012:111–8. [PubMed: 22542530]
  12. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. J Cardiovasc Pharmacol Ther. 2013:13–8. [PubMed: 22539817]
  13. Nakamura T, Hirano M, Kitta Y, Fujioka D, Saito Y, Kawabata K, Obata JE, Watanabe Y, Watanabe K, Kugiyama K. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol. 2012:12–7. [PubMed: 22445441]
  14. Pandey A Shekhar, Bissonnette S, Boukas S, Rampakakis E, Sampalis JS. Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: The EZE(STAT)2 trial. Arch Med Sci. 2011:767–75. [PMC free article: PMC3258811] [PubMed: 22291820]
  15. Uemura Y, Watarai M, Ishii H, Koyasu M, Takemoto K, Yoshikawa D, Shibata R, Matsubara T, Murohara T. Atorvastatin 10 mg plus ezetimibe 10mg compared with atorvastatin 20 mg: impact on the lipid profile in Japanese patients with abnormal glucose tolerance and coronary artery disease. J Cardiol. 2012:50–6. [PubMed: 22100058]
  16. Averna M, Missault L, Vaverkova H, Farnier M, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Taggart W, Brudi P. Lipid-altering efficacy of switching to ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk patients with and without metabolic syndrome. Diab Vasc Dis Res. 2011:262–70. [PubMed: 21859750]
  17. Ramos SC, Fonseca FA, Kasmas SH, Moreira FT, Helfenstein T, Borges NC, Moreno RA, Rezende VM, Silva FC, Izar MC. The role of soluble fiber intake in patients under highly effective lipid-lowering therapy. Nutr J. 2011:80. [PMC free article: PMC3159132] [PubMed: 21810257]
  18. Viigimaa M, Vaverkova H, Farnier M, Averna M, Missault L, Hanson ME, Dong Q, Shah A, Brudi P. Ezetimibe/simvastatin 10/20 mg versus rosuvastatin 10 mg in high-risk hypercholesterolemic patients stratified by prior statin treatment potency. Lipids Health Dis. 2010:127. [PMC free article: PMC2992529] [PubMed: 21050476]
  19. Vaverkova H, Farnier M, Averna M, Missault L, Viigimaa M, Dong Q, Shah A, Johnson-Levonas AO, Brudi P. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy. Cardiovasc Ther. 2012:61–74. [PubMed: 20626402]
  20. Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients. Curr Med Res Opin. 2010:907–15. [PubMed: 20156032]
  21. Conard S, Bays H, Leiter LA, Bird S, Lin J, Hanson ME, Shah A, Tershakovec AM. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab. 2010:210–8. [PubMed: 20151997]
  22. Goldberg RB, Guyton JR, Mazzone T, Weinstock RS, Polis AB, Tipping D, Tomassini JE, Tershakovec AM. Relationships between metabolic syndrome and other baseline factors and the efficacy of ezetimibe/simvastatin and atorvastatin in patients with type 2 diabetes and hypercholesterolemia. Diabetes Care. 2010:1021–4. [PMC free article: PMC2858166] [PubMed: 20150290]
  23. Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis. 2009:56. [PMC free article: PMC2803170] [PubMed: 20017910]
  24. Jakulj L, Vissers MN, Groen AK, Hutten BA, Lutjohann D, Veltri EP, Kastelein JJ. Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trial. J Lipid Res. 2010:755–62. [PMC free article: PMC2842149] [PubMed: 19828909]
  25. Sang ZC, Wang F, Zhou Q, Li YH, Li YG, Wang HP, Chen SY. Combined use of extended-release niacin and atorvastatin: safety and effects on lipid modification. Chin Med J (Engl) 2009:1615–20. [PubMed: 19719960]
  26. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Ueda Y, Suzuki T, Ueda S, Fukami K, Okuda S, Yamagishi S. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010:58–61. [PubMed: 19666118]
  27. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, Palumbo I, D'Angelo A, Cicero AF. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. Curr Med Res Opin. 2009:1973–83. [PubMed: 19555253]
  28. Meaney A, Ceballos G, Asbun J, Solache G, Mendoza E, Vela A, Meaney E. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009:838–47. [PubMed: 19443679]
  29. Winkler K, Schewe T, Putz G, Odunc N, Schafer G, Siegel E, Geisen U, Abletshauser C, Hoffmann MM. Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles. Eur J Clin Invest. 2009:463–70. [PubMed: 19397693]
  30. Sudhop T, Reber M, Tribble D, Sapre A, Taggart W, Gibbons P, Musliner T, von Bergmann K, Lutjohann D. Changes in cholesterol absorption and cholesterol synthesis caused by ezetimibe and/or simvastatin in men. J Lipid Res. 2009:2117–23. [PMC free article: PMC2739752] [PubMed: 19380898]
  31. Zema MJ. Add-on therapy for hypercholesterolemia: a pilot comparison of two gastrointestinally-acting agents in statin-treated patients. J Clin Lipidol. 2009:119–24. [PubMed: 21291801]
  32. Goldberg AC, Bays HE, Ballantyne CM, Kelly MT, Buttler SM, Setze CM, Sleep DJ, Stolzenbach JC. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol. 2009:515–22. [PubMed: 19195513]
  33. Maki KC, Lubin BC, Reeves MS, Dicklin MR, Harris WS. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia. J Clin Lipidol. 2009:33–8. [PubMed: 21291786]
  34. Brudi P, Reckless JP, Henry DP, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO. Efficacy of ezetimibe/simvastatin 10/40 mg compared to doubling the dose of low-, medium- and high-potency statin monotherapy in patients with a recent coronary event. Cardiology. 2009:89–97. [PubMed: 19018143]
  35. Hamilton-Craig IR. After ENHANCE: the cholesterol hypothesis is alive and well. Med J Aust. 2008:303–4. [PubMed: 18803531]
  36. Poldermans D, Dunkelgrun M, Schouten O, Hostalek U. Prolonged-release nicotinic acid in patients with atherosclerotic disease in the Netherlands. Eur Surg Res. 2008:313–8. [PubMed: 18799884]
  37. Bays H, Sapre A, Taggart W, Liu J, Capece R, Tershakovec A. Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008:2953–66. [PubMed: 18782465]
  38. Avisar I, Brook JG, Wolfovitz E. Atorvastatin monotherapy vs. combination therapy in the management of patients with combined hyperlipidemia. Eur J Intern Med. 2008:203–8. [PubMed: 18395165]
  39. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008:539–54. [PubMed: 18266852]
  40. Weinstock RS, Goldberg RB, Guyton JR, Mazzone T, Polis A, Tomassini JE, Lin J, Shah A, Tershakovec AM. Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non-HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes. J Clin Lipidol. 2008:25–35. [PubMed: 21291712]
  41. Assmann G, Kannenberg F, Ramey DR, Musliner TA, Gutkin SW, Veltri EP. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr Med Res Opin. 2008:249–59. [PubMed: 18053317]
  42. Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. Indian Heart J. 2008:215–222. [PubMed: 19240310]
  43. Rodney RA, Sugimoto D, Wagman B, Zieve F, Kerzner B, Strony J, Yang B, Suresh R, Veltri E. Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia. J Natl Med Assoc. 2006:772–8. [PMC free article: PMC2569293] [PubMed: 16749654]
  44. Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J, Ball S, Baxter A, Blackwell L, Cairns HS, Carr S, Collins R, Kourellias K, Rogerson M, Scoble JE, Tomson CR, Warwick G, Wheeler DC. The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD. Am J Kidney Dis. 2006:385–95. [PubMed: 16490616]
  45. Farnier M, Volpe M, Massaad R, Davies MJ, Allen C. Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease. Int J Cardiol. 2005:327–32. [PubMed: 15982505]
  46. Cruz-Fernandez JM, Bedarida GV, Adgey J, Allen C, Johnson-Levonas AO, Massaad R. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract. 2005:619–27. [PubMed: 15924587]
  47. Brohet C, Banai S, Alings AM, Massaad R, Davies MJ, Allen C. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin. 2005:571–8. [PubMed: 15899106]
  48. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc. 2005:587–95. [PubMed: 15887425]
  49. Masana L, Mata P, Gagne C, Sirah W, Cho M, Johnson-Levonas AO, Meehan A, Troxell JK, Gumbiner B. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin Ther. 2005:174–84. [PubMed: 15811480]
  50. Grundy SM, Vega GL, Yuan Z, Battisti WP, Brady WE, Palmisano J. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial) Am J Cardiol. 2005:462–8. [PubMed: 15695129]
  51. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation. 2004:3512–7. [PubMed: 15537681]
  52. Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD. Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia. Prev Cardiol. 2004:176–81. [PubMed: 15539964]
  53. Kosoglou T, Statkevich P, Yang B, Suresh R, Zhu Y, Boutros T, Maxwell SE, Tiessen R, Cutler DL. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin. 2004:1185–95. [PubMed: 15324521]
  54. Ballantyne CM, Lipka LJ, Sager PT, Strony J, Alizadeh J, Suresh R, Veltri EP. Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia. Int J Clin Pract. 2004:653–8. [PubMed: 15311720]
  55. Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol. 2004:1487–94. [PubMed: 15194018]
  56. Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004:137–51. [PubMed: 15063607]
  57. Melani L, Mills R, Hassman D, Lipetz R, Lipka L, LeBeaut A, Suresh R, Mukhopadhyay P, Veltri E. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003:717–28. [PubMed: 12713766]
  58. Gagne C, Bays HE, Weiss SR, Mata P, Quinto K, Melino M, Cho M, Musliner TA, Gumbiner B. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002:1084–91. [PubMed: 12423708]
  59. Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA. Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002:2377–86. [PubMed: 12145148]
  60. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care. 2002:1198–202. [PubMed: 12087019]
  61. Chan DC, Watts GF, Mori TA, Barrett PH, Beilin LJ, Redgrave TG. Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity. Eur J Clin Invest. 2002:429–36. [PubMed: 12059988]
  62. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002:2469–75. [PubMed: 12034651]
  63. Chan DC, Watts GF, Barrett PH, Beilin LJ, Mori TA. Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity. Clin Chem. 2002:877–83. [PubMed: 12029003]
  64. Davidson MH, Toth P, Weiss S, McKenney J, Hunninghake D, Isaacsohn J, Donovan JM, Burke SK. Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Clin Cardiol. 2001:467–74. [PubMed: 11403509]
  65. Nordoy A, Hansen JB, Brox J, Svensson B. Effects of atorvastatin and omega-3 fatty acids on LDL subfractions and postprandial hyperlipemia in patients with combined hyperlipemia. Nutr Metab Cardiovasc Dis. 2001:7–16. [PubMed: 11383326]
  66. Durrington PN, Bhatnagar D, Mackness MI, Morgan J, Julier K, Khan MA, France M. An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia. Heart. 2001:544–8. [PMC free article: PMC1729738] [PubMed: 11303007]
  67. Simons LA. Comparison of atorvastatin alone versus simvastatin +/- cholestyramine in the management of severe primary hypercholesterolaemia (the six cities study) Aust N Z J Med. 98:327–33. [PubMed: 9673745]
  68. Eriksson M, Hadell K, Holme I, Walldius G, Kjellstrom T. Compliance with and efficacy of treatment with pravastatin and cholestyramine: a randomized study on lipid-lowering in primary care. J Intern Med. 98:373–80. [PubMed: 9651560]
  69. Simons LA, Sullivan D, Simons J, Celermajer DS. Effects of atorvastatin monotherapy and simvastatin plus cholestyramine on arterial endothelial function in patients with severe primary hypercholesterolaemia. Atherosclerosis. 98:197–203. [PubMed: 9568752]
  70. Nordoy A, Bonaa KH, Nilsen H, Berge RK, Hansen JB, Ingebretsen OC. Effects of Simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia. J Intern Med. 98:163–70. [PubMed: 9566646]
  71. Ito MK, Shabetai R. Pravastatin alone and in combination with low-dose cholestyramine in patients with primary hypercholesterolemia and coronary artery disease. Am J Cardiol. 97:799–802. [PubMed: 9315597]
  72. Davidson MH, Macariola-Coad JR, McDonald AM, Maki KC, Hall HA. Separate and joint effects of marine oil and simvastatin in patients with combined hyperlipidemia. Am J Cardiol. 97:797–8. [PubMed: 9315596]
  73. Gardner SF, Schneider EF, Granberry MC, Carter IR. Combination therapy with low-dose lovastatin and niacin is as effective as higher-dose lovastatin. Pharmacotherapy. 96:419–23. [PubMed: 8726600]
  74. Vanhanen HT, Miettinen TA. Cholesterol absorption and synthesis during pravastatin, gemfibrozil and their combination. Atherosclerosis. 95:135–46. [PubMed: 7661873]
  75. O'Keefe JH Jr, Harris WS, Nelson J, Windsor SL. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol. 95:480–4. [PubMed: 7653448]
  76. Sprecher DL, Abrams J, Allen JW, Keane WF, Chrysant SG, Ginsberg H, Fischer JJ, Johnson BF, Theroux P, Jokubaitis L. Low-dose combined therapy with fluvastatin and cholestyramine in hyperlipidemic patients. Ann Intern Med. 94:537–43. [PubMed: 8093139]
  77. Simons LA, Simons J, Parfitt A. Successful management of primary hypercholesterolaemia with simvastatin and low-dose colestipol. Med J Aust. 92:455–9. [PubMed: 1406395]
  78. O'Brien RC, Simons LA, Clifton P, Cooper ME, Jennings GL, Jerums G, Nestel PJ, Sullivan D. Comparison of simvastatin and cholestyramine in the treatment of primary hypercholesterolaemia. Med J Aust. 90:480–3. [PubMed: 2199801]
  79. Blagden MD, Chipperfield R. Efficacy and safety of ezetimibe co-administered with atorvastatin in untreated patients with primary hypercholesterolaemia and coronary heart disease. Curr Med Res Opin. 2007:767–75. [PubMed: 17407633]
  80. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007:1090–8. [PubMed: 17398308]
  81. Ballantyne CM, Weiss R, Moccetti T, Vogt A, Eber B, Sosef F, Duffield E. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study) Am J Cardiol. 2007:673–80. [PubMed: 17317370]
  82. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, Krone W, Gouni-Berthold I. Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf. 2006:703–12. [PubMed: 16872244]
  83. Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, Kakafika AI, Tziomalos K, Burroughs AK, Elisaf MS. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006:873–83. [PubMed: 16709309]
  84. Muhlestein JB, May HT, Jensen JR, Horne BD, Lanman RB, Lavasani F, Wolfert RL, Pearson RR, Yannicelli HD, Anderson JL. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study. J Am Coll Cardiol. 2006:396–401. [PubMed: 16843192]
  85. Chenot F, Montant PF, Marcovitch O, Blaimont M, de Meester A, Descamps OS. Co-administration of ezetimibe and simvastatin in acute myocardial infarction. Eur J Clin Invest. 2007:357–63. [PubMed: 17461981]
  86. Shankar PK, Bhat R, Prabhu M, Reddy BP, Reddy MS, Reddy M. Efficacy and tolerability of fixed-dose combination of simvastatin plus ezetimibe in patients with primary hypercholesterolemia: Results of a multicentric trial from India. J Clin Lipidol. 2007:264–70. [PubMed: 21291690]
  87. Kuvin JT, Dave DM, Sliney KA, Mooney P, Patel AR, Kimmelstiel CD, Karas RH. Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol. 2006:743–5. [PubMed: 16950175]
  88. Isaacsohn JL, Bakker-Arkema RG, Fayyad R, Whitcomb R, Black DM. Atorvastatin, a New HMG-CoA Reductase Inhibitor, Does Not Affect Glucocorticoid Hormones in Patients With Hypercholesterolemia. J Cardiovasc Pharmacol Ther. 97:243–249. [PubMed: 10684465]
  89. Kastelein JJ, Akdim F, Stroes ES, Zwinderman AH, Bots ML, Stalenhoef AF, Visseren FL, Sijbrands EJ, Trip MD, Stein EA, Gaudet D, Duivenvoorden R, Veltri EP, Marais AD, de Groot E. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med. 2008:1431–43. [PubMed: 18376000]
  90. Stein EA, Davidson MH, Dujovne CA, Hunninghake DB, Goldberg RB, Illingworth DR, Knopp RH, Miller VT, Frost P, Isaacsohn JL, Mitchel YB, Melino MR, Shapiro D, Tobert JA. Efficacy and Tolerability of Low-dose Simvastatin and Niacin, Alone and in Combination, in Patients With Combined Hyperlipidemia: A Prospective Trial. J Cardiovasc Pharmacol Ther. 96:107–116. [PubMed: 10684407]
  91. Stein EA, Ballantyne CM, Windler E, Sirnes PA, Sussekov A, Yigit Z, Seper C, Gimpelewicz CR. Efficacy and tolerability of fluvastatin XL 80 mg alone, ezetimibe alone, and the combination of fluvastatin XL 80 mg with ezetimibe in patients with a history of muscle-related side effects with other statins. Am J Cardiol. 2008:490–6. [PubMed: 18312764]
  92. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation. 2007:230–5. [PubMed: 17687635]
  93. Reckless JP, Henry P, Pomykaj T, Lim ST, Massaad R, Vandormael K, Johnson-Levonas AO, Lis K, Brudi P, Allen C. Lipid-altering efficacy of ezetimibe/simvastatin 10/40 mg compared with doubling the statin dose in patients admitted to the hospital for a recent coronary event: the INFORCE study. Int J Clin Pract. 2008:539–54. [PubMed: 18266852]
  94. Turk TR, Voropaeva E, Kohnle M, Nurnberger J, Philipp T, Kribben A, Heemann U, Witzke O. Ezetimibe treatment in hypercholesterolemic kidney transplant patients is safe and effective and reduces the decline of renal allograft function: a pilot study. Nephrol Dial Transplant. 2008:369–73. [PubMed: 17956887]
  95. Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, Stier S, Ko Y, Patel D, Soutar AK, Seedorf U, Mantzoros CS, Plat J, Krone W. Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis. 2008:198–207. [PubMed: 17980884]
  96. Moore A, Phan BA, Challender C, Williamson J, Marcovina S, Zhao XQ. Effects of adding extended-release niacin and colesevelam to statin therapy on lipid levels in subjects with atherosclerotic disease. J Clin Lipidol. 2007:620–5. [PubMed: 21291704]
  97. Guyton JR, Goldberg RB, Mazzone T, Weinstock RS, Polis A, Rosenberg E, Tershakovec AM. Lipoprotein and apolipoprotein ratios in the VYTAL trial of ezetimibe/simvastatin compared with atorvastatin in type 2 diabetes. J Clin Lipidol. 2008:19–24. [PubMed: 21291711]
  98. Ballantyne CM, Davidson MH, McKenney JM, Keller LH, Bajorunas DR, Karas RH. Comparison of the efficacy and safety of a combination tablet of niacin extended-release and simvastatin with simvastatin 80 mg monotherapy: the SEACOAST II (high-dose) study. J Clin Lipidol. 2008:79–90. [PubMed: 21291724]
  99. Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008:1489–94. [PubMed: 19026302]
  100. Leiter LA, Bays H, Conard S, Bird S, Rubino J, Hanson ME, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (40 mg) compared with uptitration of atorvastatin (to 80 mg) in hypercholesterolemic patients at high risk of coronary heart disease. Am J Cardiol. 2008:1495–501. [PubMed: 19026303]
PubReader format: click here to try
Cover of Combination Therapy Versus Intensification of Statin Monotherapy: An Update
Combination Therapy Versus Intensification of Statin Monotherapy: An Update [Internet].
Comparative Effectiveness Reviews, No. 132.
Monroe AK, Gudzune KA, Sharma R, et al.

PubMed Health Blog...

read all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...